Last edition
News about
Promoters of Sudeep Pharma Completes Acquisition from JRS Pharma
Sudeep Pharma Pvt. Ltd.’s promoters have completed the acquisition of shares from their joint venture partners – JRS PHARMA, regaining 100 percent ownership of the company.
Sanofi Starts Shipping US Influenza Vaccines for 2024-25
Sanofi has begun shipped its first influenza (flu) vaccines across the U.S. in preparation for the 2024–25 flu season.
Alembic Pharma Gets USFDA Approval for Bromfenac Ophthalmic Solution
Alembic Pharmaceuticals has secured final approval from the US Food and Drug Administration (USFDA) for its generic Bromfenac Ophthalmic Solution.
Pint Pharma Announces Approval of ORLADEYO in Peru
Pint Pharma has announced that the General Directorate of Medicines Supplies and Drugs (DIGEMID) in Peru has announced the approval of ORLADEYO (berotralstat) for prophylaxis of hereditary angioedema (HAE) attacks in adults and children 12 years and older.
Life Molecular Imaging Expands Partnership with Jubilant Radiopharma to Distribute Neurace
Life Molecular Imaging (LMI) has expanded their strategic partnership and licensing agreement with Jubilant Radiopharma to provide and distribute Neuraceq from Jubilant's single photon emission computed tomography (SPECT) and Positron Emision Tomography (PET) radiopharmaceutical manufacturing site located in Mobile, AL.
MedPharm Announces Merger with Tergus Pharma
MedPharm, Ltd. has announced a merger with Tergus Pharma, a Great Point Partners portfolio company.
Lupin Gets Tentative Approval from US FDA for Empagliflozin, Linagliptin and Metformin Hydrochloride
Lupin has secured tentative approval from the United States Food and Drug Administration (US FDA)for its Abbreviated New Drug Application for Empagliflozin, Linagliptin and Metformin Hydrochloride Extended-Release (ER) Tablets.
TuHURA Biosciences Signs Exclusivity and Right of First Offer Deal for Kineta
TuHURA Biosciences, Inc. has entered into an Exclusivity and Right of First Offer Agreement with Kineta, Inc. for the potential acquisition of Kineta's KVA12123 anti-VISTA antibody and related rights and assets associated with and derived from the asset.
CASI Pharmaceuticals Appoints Daniel Lang as New CFO and SVP
CASI Pharmaceuticals, Inc. has appointed Daniel Lang, MD as Chief Financial Officer and Senior Vice President.
Lilly to Acquire Morphic to Enhance Outcomes for Patients with IBD
Eli Lilly and Company has signed a definitive agreement to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for the treatment of serious chronic diseases.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy